Roche's KRAS drug divarasib shows impressive lung cancer data at ESMO

Roche presented data on its KRAS-targeted drug divarasib at this year’s European Society for Medical Oncology congress, in results STAT News described as among the more impressive data sets at the meeting. The study examined divarasib’s performance in treating lung cancer.

KRAS mutations drive a significant share of lung cancers and were, for decades, considered undruggable by the pharmaceutical industry. Roche’s divarasib is part of a newer wave of compounds designed to target these mutations directly, following earlier approvals of KRAS inhibitors from other manufacturers for similar indications.

STAT News reported the ESMO data as a win for Roche’s lung cancer program, though the publication’s full account of the trial’s specific findings, patient population, and comparative results sits behind STAT’s subscription paywall. The report identifies divarasib as a KRAS drug and frames the ESMO presentation as notable within the broader field of lung cancer treatment research presented at the congress.

No additional detail on dosing, trial phase, patient outcomes, or regulatory next steps was available in the material reviewed. The observatory notes the development as part of the ongoing effort among pharmaceutical companies to expand treatment options for KRAS-mutant lung cancers, an area of active competition and research following the earlier breakthroughs that first made this mutation class druggable.